keyword
MENU ▼
Read by QxMD icon Read
search

Antipsychotic induced weight gain

keyword
https://www.readbyqxmd.com/read/27898069/clozapine-modifies-the-differentiation-program-of-human-adipocytes-inducing-browning
#1
E Kristóf, Q-M Doan-Xuan, A K Sárvári, Á Klusóczki, P Fischer-Posovszky, M Wabitsch, Z Bacso, P Bai, Z Balajthy, L Fésüs
Administration of second-generation antipsychotic drugs (SGAs) often leads to weight gain and consequent cardio-metabolic side effects. We observed that clozapine but not six other antipsychotic drugs reprogrammed the gene expression pattern of differentiating human adipocytes ex vivo, leading to an elevated expression of the browning marker gene UCP1, more and smaller lipid droplets and more mitochondrial DNA than in the untreated white adipocytes. Laser scanning cytometry showed that up to 40% of the differentiating single primary and Simpson-Golabi-Behmel syndrome (SGBS) adipocytes had the characteristic morphological features of browning cells...
November 29, 2016: Translational Psychiatry
https://www.readbyqxmd.com/read/27855565/impact-of-histamine-receptors-h1-and-h3-polymorphisms-on-antipsychotic-induced-weight-gain
#2
Arun K Tiwari, Danning Zhang, Jennie G Pouget, Clement C Zai, Nabilah I Chowdhury, Eva J Brandl, Li Qin, Natalie Freeman, Jeffrey A Lieberman, Herbert Y Meltzer, James L Kennedy, Daniel J Müller
OBJECTIVES: A positive correlation between antipsychotic-induced weight gain (AIWG) and antipsychotic drugs' antagonist effect at histamine H1 receptor (HRH1) as well as agonist effect at histamine H3 receptor (HRH3) in the brain has been consistently demonstrated. We investigated the potential impact of single-nucleotide polymorphisms (SNPs) in HRH1 and HRH3 genes on AIWG. METHODS: We analysed 40 tagSNPs in HRH1 (n = 34) and HRH3 (n = 6) in schizophrenia/schizoaffective disorder patients (n = 193) primarily treated with clozapine or olanzapine for up to 14 weeks...
November 18, 2016: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/27846426/metabolic-outcomes-of-bergamot-polyphenolic-fraction-administration-in-patients-treated-with-second-generation-antipsychotics-a-pilot-study
#3
Antonio Bruno, Gianluca Pandolfo, Manuela Crucitti, Antonino Maisano, Rocco A Zoccali, Maria Rosaria Anna Muscatello
Second-generation antipsychotics (SGAs) are notoriously associated with a marked increase in body weight and with a wide range of metabolic adverse effects, and their chronic use is related with an increased risk for the development of metabolic syndrome (MS). Different adjunctive treatments have been proposed to reduce SGAs-induced weight gain and/or metabolic abnormalities with inconsistent or too limited evidence to support their regular clinical use, thus suggesting the need to find new possible treatments...
October 22, 2016: Journal of Nutritional Biochemistry
https://www.readbyqxmd.com/read/27845774/serum-metabolite-profile-associates-with-the-development-of-metabolic-co-morbidities-in-first-episode-psychosis
#4
T Suvitaival, O Mantere, T Kieseppä, I Mattila, P Pöhö, T Hyötyläinen, J Suvisaari, M Orešič
Psychotic patients are at high risk for developing obesity, metabolic syndrome and type 2 diabetes. These metabolic co-morbidities are hypothesized to be related to both treatment side effects as well as to metabolic changes occurring during the psychosis. Earlier metabolomics studies have shown that blood metabolite levels are predictive of insulin resistance and type 2 diabetes in the general population as well as sensitive to the effects of antipsychotics. In this study, we aimed to identify the metabolite profiles predicting future weight gain and other metabolic abnormalities in psychotic patients...
November 15, 2016: Translational Psychiatry
https://www.readbyqxmd.com/read/27818703/the-relationship-between-body-weight-change-and-body-constitutions-of-traditional-chinese-medicine-in-patients-with-schizophrenia
#5
Jui-Fen Cheng, Xuan-Yi Huang, Te-Le Liu, Ruey-Yun Wang, Han-Yi Ching
Objective. To explore the relationship between body constitution (BC) types and weight change in patients with schizophrenia and who underwent second-generation antipsychotics (SGAs) treatment. Method. Body weight and waist circumference of eighty-five participants were measured for 6 consecutive weeks. Constitutions of Yin-Xu, Yang-Xu, and Stasis were assessed using the Body Constitution Questionnaire (BCQ). Results. Participants with body constitutions Yin-Xu (50.6%), Yang-Xu (49.4%), or Stasis (38.8%) exhibited worse physical condition and unhealthy daily habits, particularly in Stasis constitution...
2016: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/27721972/significant-weight-loss-following-clozapine-use-how-is-it-possible-a-case-report-and-review-of-published-cases-and-literature-relevant-to-the-subject
#6
Tongeji E Tungaraza
It has been repeatedly shown that clozapine is more efficacious than other antipsychotics in the management of treatment-resistant schizophrenia. However, clozapine is associated with a number of side effects including weight gain. Antipsychotic-induced weight gain has been linked with a number of untoward events including psychological factors such as stigma and low self-esteem, and physical factors such as metabolic syndromes and untimely death. The mechanism underlying antipsychotic (including clozapine)-induced weight gain is not clearly understood, although it is said to involve several brain areas, several neurotransmitters, neuropeptides and genetic factors...
October 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/27716110/metformin-in-prevention-and-treatment-of-antipsychotic-induced-weight-gain-a-systematic-review-and-meta-analysis
#7
Varuni Asanka de Silva, Chathurie Suraweera, Suhashini S Ratnatunga, Madhubashinee Dayabandara, Nimali Wanniarachchi, Raveen Hanwella
BACKGROUND: Most antipsychotics are associated with weight gain and other metabolic complications. Several randomized trials have shown metformin to be effective, but this still hasn't been included in clinical guidelines on managing antipsychotic induced weight gain. METHODS: All double blind placebo controlled trials assessing the efficacy of metformin in the treatment of antipsychotic induced weight gain were included. Cochrane Central Register of Controlled Trials (CENTRAL) and MEDLINE were searched for the period January 2000-December 2015...
October 3, 2016: BMC Psychiatry
https://www.readbyqxmd.com/read/27681143/genetic-determinants-of-clozapine-induced-metabolic-side-effects
#8
Kamini Vasudev, Yun-Hee Choi, Ross Norman, Richard B Kim, Ute I Schwarz
OBJECTIVE: Atypical antipychotics are linked to a higher incidence of metabolic side effects, including weight gain, dyslipidemia, and diabetes. In this study, we examined the prevalence and potential genetic predictors of metabolic side effects in 60 adult patients on clozapine. METHOD: Genetic variants of relevance to clozapine metabolism, clearance, and response were assessed through targeted genotyping of cytochrome P450 enzymes CYP1A2 and CYP2C19, the efflux transporter ABCB1, the serotonin receptor (HTR2C), leptin (LEP), and leptin receptor (LEPR)...
September 28, 2016: Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie
https://www.readbyqxmd.com/read/27672485/brexpiprazole-a-new-treatment-option-for-schizophrenia
#9
REVIEW
Jonathan R Scarff
Schizophrenia occurs in approximately 0.3 to 0.7 percent of the world's population and is associated with significant morbidity and mortality. Although atypical antipsychotics reduce positive and negative symptoms, they are associated with varying degrees of metabolic adverse effects. This necessitates continued development of efficacious yet metabolically favorable treatments. This article reviews brexpiprazole, a medication recently approved to treat patients with schizophrenia. Brexpiprazole was well-tolerated, and adverse reactions were statistically insignificant...
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27610173/negative-correlation-between-serum-s100b-and-leptin-levels-in-schizophrenic-patients-during-treatment-with-clozapine-and-risperidone-preliminary-evidence
#10
Narjes Hendouei, Seyed Hamzeh Hosseini, Amin Panahi, Zahra Khazaeipour, Fatemeh Barari, Adeleh Sahebnasagh, Shahram Ala
Recently, extensive efforts have been made to understand the rate of energy expenditure and the weight gain associated with atypical antipsychotic treatment, including identification of markers of obesity risk. In recent years, leptin, an adipocyte hormone, has gained significant interest in psychiatric disorders. S100B has been considered as a surrogate marker for astrocyte-specific damage in neurologic disorders. Also, S100B has been detected in adipose with concentration as high as nervous tissue as a second release source...
2016: Iranian Journal of Pharmaceutical Research: IJPR
https://www.readbyqxmd.com/read/27606321/genetics-of-common-antipsychotic-induced-adverse-effects
#11
REVIEW
Raymond R MacNeil, Daniel J Müller
The effectiveness of antipsychotic drugs is limited due to accompanying adverse effects which can pose considerable health risks and lead to patient noncompliance. Pharmacogenetics (PGx) offers a means to identify genetic biomarkers that can predict individual susceptibility to antipsychotic-induced adverse effects (AAEs), thereby improving clinical outcomes. We reviewed the literature on the PGx of common AAEs from 2010 to 2015, placing emphasis on findings that have been independently replicated and which have additionally been listed to be of interest by PGx expert panels...
July 2016: Molecular Neuropsychiatry
https://www.readbyqxmd.com/read/27606316/inflammatory-cytokines-and-antipsychotic-induced-weight-gain-review-and-clinical-implications
#12
REVIEW
Trehani M Fonseka, Daniel J Müller, Sidney H Kennedy
Antipsychotic medications (APs), particularly second-generation APs, are associated with significant weight gain in schizophrenia patients. Recent evidence suggests that the immune system may contribute to antipsychotic-induced weight gain (AIWG) via AP-mediated alterations of cytokine levels. Antipsychotics with a high propensity for weight gain, such as clozapine and olanzapine, influence the expression of immune genes, and induce changes in serum cytokine levels to ultimately down-regulate neuroinflammation...
May 2016: Molecular Neuropsychiatry
https://www.readbyqxmd.com/read/27593622/h1-histamine-receptor-affinity-predicts-weight-gain-with-antidepressants
#13
Virginio Salvi, Claudio Mencacci, Francesco Barone-Adesi
Weight gain and metabolic abnormalities are extensively found in patients taking psychotropic medications. Although mainly antipsychotics have been implicated, also antidepressants carry the potential to induce weight gain, with tricyclics and mirtazapine being associated with the greatest weight gain. It has been suggested that this could be due to the different ability of antidepressants to block adrenergic, cholinergic, and histaminergic postsynaptic receptors. To date, however, the link between antidepressant-induced weight gain and their receptor affinity profile has not been established...
October 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27556593/metformin-for-treatment-of-overweight-induced-by-atypical-antipsychotic-medication-in-young-people-with-autism-spectrum-disorder-a-randomized-clinical-trial
#14
Evdokia Anagnostou, Michael G Aman, Benjamin L Handen, Kevin B Sanders, Amy Shui, Jill A Hollway, Jessica Brian, L Eugene Arnold, Lucia Capano, Jessica A Hellings, Eric Butter, Deepali Mankad, Rameshwari Tumuluru, Jessica Kettel, Cassandra R Newsom, Stasia Hadjiyannakis, Naomi Peleg, Dina Odrobina, Sarah McAuliffe-Bellin, Pearl Zakroysky, Sarah Marler, Alexis Wagner, Taylor Wong, Eric A Macklin, Jeremy Veenstra-VanderWeele
IMPORTANCE: Atypical antipsychotic medications are indicated for the treatment of irritability and agitation symptoms in children with autism spectrum disorder (ASD). Unfortunately, these medications are associated with weight gain and metabolic complications that are especially troubling in children and with long-term use. OBJECTIVE: To evaluate the efficacy of metformin for weight gain associated with atypical antipsychotic medications in children and adolescents with ASD (defined in the protocol as DSM-IV diagnosis of autistic disorder, Asperger disorder, or pervasive developmental disorder not otherwise specified), aged 6 to 17 years...
September 1, 2016: JAMA Psychiatry
https://www.readbyqxmd.com/read/27556412/atypical-antipsychotic-induced-weight-gain-in-children-and-adolescents-sometimes-less-is-more
#15
Christopher J McDougle
No abstract text is available yet for this article.
September 1, 2016: JAMA Psychiatry
https://www.readbyqxmd.com/read/27548055/metformin-induced-type-1-hypersensitivity-in-a-child-with-antipsychotic-induced-weight-gain
#16
Constance Mennella, Daniel P Dickstein
No abstract text is available yet for this article.
August 22, 2016: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/27504985/olanzapine-depot-administration-induces-time-dependent-changes-in-adipose-tissue-endocrine-function-in-rats
#17
Katerina Horska, Jana Ruda-Kucerova, Zuzana Babinska, Michal Karpisek, Regina Demlova, Radka Opatrilova, Pavel Suchy, Hana Kotolova
OBJECTIVE: Metabolic adverse effects of atypical antipsychotics (AAP) contribute significantly to increased risk of cardiovascular morbidity and mortality in patients suffering from schizophrenia. Extensive preclinical research has addressed this issue over the past years, though mechanisms underlying these adverse effects of AAP are still not understood completely. Recently, attention is drawn towards the role of adipose tissue metabolism and neurohormonal regulations. METHODS: The aim of this study was to evaluate the time-dependent effects of olanzapine depot administration at clinically relevant dosing on the regulation of energy homeostasis, glucose and lipid metabolism, gastrointestinal and adipose tissue-derived hormones involved in energy balance regulations in female Sprague-Dawley rats...
November 2016: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/27449495/hepatic-safety-of-atypical-antipsychotics-current-evidence-and-future-directions
#18
REVIEW
Mahmoud Slim, Inmaculada Medina-Caliz, Andres Gonzalez-Jimenez, M Rosario Cabello, Fermin Mayoral-Cleries, M Isabel Lucena, Raul J Andrade
The newer atypical antipsychotic agents (AAPs) represent an attractive therapeutic option for a wide range of psychotic disorders, including schizophrenia and bipolar mania, because of the reduced risk of disabling extrapyramidal symptoms. However, their growing use has raised questions about their tolerability over the endocrine, metabolic, and cardiovascular axes. Indeed, atypical antipsychotic drugs are associated, to differing extents, with mild elevation of aminotransferases related to weight gain, AAP-induced metabolic syndrome, and nonalcoholic fatty liver disease...
October 2016: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/27414739/-759c-t-polymorphism-of-the-htr2c-gene-is-associated-with-second-generation-antipsychotic-induced-weight-gain-in-female-patients-with-schizophrenia
#19
F M Daray, D Rodante, L G Carosella, M E Silva, M Martínez, M V Fernández Busch, D F Faccone, R P Rothlin, P C Maffía
Introduction: The HTR2C gene is an important candidate in pharmacogenetic studies of antipsychotic-induced weight gain (AIWG). However, inconsistent results have been obtained. The present study investigated the association between -759C>T, functional polymorphism of the HTR2C receptor, and AIWG. Methods: A prospective cohort of 48 female inpatients with schizophrenia and related illness treated according to normal clinical practice with second generation antipsychotics (SGAs) risperidone, clozapine, quetiapine, and olanzapine were evaluated...
July 14, 2016: Pharmacopsychiatry
https://www.readbyqxmd.com/read/27364609/development-of-cns-multi-receptor-ligands-modification-of-known-d2-pharmacophores
#20
Jagan R Etukala, Xue Y Zhu, Suresh V K Eyunni, Edem K Onyameh, Edward Ofori, Barbara A Bricker, Hye J Kang, Xi-Ping Huang, Bryan L Roth, Seth Y Ablordeppey
Several known D2 pharmacophores have been explored as templates for identifying ligands with multiple binding affinities at dopamine and serotonin receptors considered as clinically relevant receptors in the treatment of neuropsychiatric diseases. This approach has resulted in the identification of ligands that target multiple CNS receptors while avoiding others associated with deleterious effects. In particular, compounds 11, 15 and 22 may have potential for further development as antipsychotic agents as they favorably interact with the clinically relevant receptors including D2R, 5-HT1AR, and 5-HT7R...
August 15, 2016: Bioorganic & Medicinal Chemistry
keyword
keyword
99026
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"